Construction and investigation of a combined hypoxia and stemness index IncRNA-associated ceRNA regulatory network in lung adenocarcinoma

Lili Guo¹, Hongxia Li¹, Weiying Li² and Junfang Tang¹*

Abstract
Hypoxia and stemness are important factors in tumor progression. We aimed to explore the ncRNA classifier associated with hypoxia and stemness in lung adenocarcinoma (LUAD). We found that the prognosis of LUAD patients with high hypoxia and stemness index was worse than that of patients with low hypoxia and stemness index. RNA expression profiles of these two clusters were analyzed, and 6867 differentially expressed (DE) mRNAs were screened. Functional analysis showed that DE mRNAs were associated with cell cycle and DNA replication. Protein–protein interaction network analysis revealed 20 hub genes, among which CENPF, BUB1, BUB1B, KIF23 and TTK had significant influence on prognosis. In addition, 807 DE IncRNAs and 243 DE miRNAs were identified. CeRNA network analysis indicated that AC079160.1-miR-539-5p-CENPF may be an important regulatory axis that potentially regulates the progression of LUAD. The expression of AC079160.1 and CENPF were positively correlated with hypoxia and stemness index, while miR-539-5p expression level was negatively correlated with hypoxia and stemness index. Overall, we identified CENPF, BUB1, BUB1B, KIF23 and TTK as potentially key genes involved in regulating hypoxia-induced tumor cell stemness, and found that AC079160.1-miR-539-5p-CENPF axis may be involved in regulating hypoxia induced tumor cell stemness in LUAD.

Keywords: Lung adenocarcinoma, Hypoxia, Stemness, ceRNA, Differentially expressed gene

Introduction
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world [1]. Lung adenocarcinoma (LUAD) is one of the common pathological types of lung cancer [2]. In recent years, the incidence of LUAD in many countries and regions has exceeded that of squamous cell carcinoma, becoming the most common pathological type of lung cancer [3]. The 5-year survival rate of LUAD is only about 15% [4]. The prognosis of LUAD patients is extremely unsatisfactory [4]. Therefore, the treatment of LUAD must start from the "root". Cancer stem cell theory proposes that in addition to ordinary tumor cells, there are a small number of tumor-propagating cells that can self-renew, continue to proliferate and differentiate [5, 6]. These cells are the seed of a poor prognosis such as tumor recurrence, metastasis and chemotherapy resistance [4, 5]. In recent years, cancer stem cells have been successfully isolated from more and more different types of cancer cells, which provides a solid basis for stem cell theory and makes cancer stem cells become a hot research topic in the field of cancer [7, 8].

*Correspondence: tangj1969@163.com
¹ Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No. 1 Beiguandaje, Tongzhou District, Beijing 101149, China
Full list of author information is available at the end of the article

© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Hypoxia is an important feature of microenvironment in solid tumor [9, 10]. During the occurrence and development of malignant tumors, due to the imbalance between the growth rate of tumor tissue and the oxygen supply capacity of the tissue, the solid tumor tissue survives in a special hypoxic microenvironment [9, 11]. Hypoxia is closely related to tumor invasion and metastasis [12]. In the hypoxic microenvironment, the tumor cells adapt to the environment to screen out the tumor cells with strong invasive ability, namely tumor stem cells [13]. By changing epigenetics and genetic stability, tumor stem cells with different clonal subpopulations, growth rates and degrees of chemotherapy resistance can be generated [14]. However, these factors have not meant considered for the treatment of LUAD because of the lack of effective biomarkers.

Most of the human genome is non-coding regions, which are transcribed to non-coding RNA (ncRNA). Although ncRNA cannot be translated into protein, it can affect human physiological and pathological processes by directly or indirectly regulating mRNA [15, 16]. In 2011, Salmena et al. proposed the competitive endogenous RNA (ceRNA) hypothesis [17]. The hypothesis holds that microRNA (miRNA) is the core element in the ceRNA network, while long non-coding RNA (lncRNA), etc., competes with ceRNA for one or more miRNA reaction elements to regulate the function of other RNAs [17, 18]. Studies have shown that ceRNA network plays an important regulatory role in the regulation of cell cycle and cell death in various malignant tumors such as lung cancer, affects tumor invasion and migration, thereby playing a critical role in the occurrence and development of tumors [19, 20]. ncRNA can be used as a potential target marker for early diagnosis, treatment and prognosis of tumors [21–23]. However, the relationship between LUAD hypoxic microenvironment, tumor stemness and ceRNA still needs further study.

The Cancer Genome Atlas (TCGA) is a publicly funded project that provides public cancer data sets to improve diagnostic methods, treatment standards, and ultimately prevent cancer [24]. In this study, the bioinformatics analysis method was used to analyze expression data of LUAD in the TCGA database, seeking to develop a hypoxic and stemness related ncRNA classifier to provide new ideas for the prognosis of LUAD.

Methods

Dataset
RNA sequencing data and corresponding clinical data of LUAD patients were downloaded from TCGA and GEO (GSE31210) databases. Hypoxia index was calculated using GSVA algorithm according to the hypoxia system-related metagene clusters [25, 26]. mRNA expression-based stemness index (mRNAsi) is an index that describes the similarity between cancer cells and stem cells, and it might be considered a quantitative form of cancer stem cells. The mRNAsi of LUAD cases were obtained from previous studies [27]. Unsupervised two-dimensional hierarchical clustering was applied to cluster the LUAD samples, and the similarity between the samples was evaluated using the Euclidean distance. Differences in prognosis among different clusters were analyzed by Kaplan–Meier curve and log-rank test.

Screening for differentially expressed (DE) mRNA, IncRNA and miRNA
Paired t-test was used to screen DE mRNA, IncRNA or miRNA between cluster 3 and cluster 4, and multiple P-value correction was performed for multiple tests. mRNA, IncRNA or miRNA with fold change (FC) > 1.5 and P<0.05 were selected as differentially expressed genes.

Functional characterization of DE mRNAs
The biological function of DE mRNAs was characterized by gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. The threshold of enrichment significance was P<0.05. Protein-protein interaction (PPI) network was constructed using Cytoscape software (https://www.cytoscape.org). The DE genes were ranked according to Maximal Clique Centrality (MCC) score, and the top 20 were identified as hub genes.

Prognostic analysis
In order to evaluate the impact of hub genes expression on patient survival, we downloaded the mRNA expression data and clinical information from TCGA and Kaplan Meier-plotter databases, respectively. According to the gene expression level, patients were divided into high expression group and low expression group. The overall survival (OS) of patients with LUAD were assessed using Kaplan–Meier survival plot.

Kaplan–Meier curve and log-rank test was also performed to predict the effect of DE IncRNA and DE miRNA on prognosis. The overall hazard ratios (HRs) with 95% confidence interval (CI) were calculated to evaluate the prognostic role of differentially expressed IncRNA or miRNA on patients with LUAD.

To assess the effect of the copy number of DE gene on prognosis, cBioPortal database (https://www.cbioportal.org/) was applied to analysis the alteration frequency of gene. Patients were divided into altered group and
unaltered group. The overall survival was assessed using Kaplan–Meier curve.

Construction and correlation analysis of ceRNA network
Hub genes, DE lncRNAs and DE miRNAs that significantly affected prognosis were applied to construct the ceRNA network. StarBase (https://starbase.sysu.edu.cn/) was used to establish ceRNA network. Cytoscape software was used to visualize the ceRNA network. Correlation analysis of node expression in ceRNA network with hypoxia and stemness index was performed using R software program.

Statistical analysis
Statistical analysis was performed using R software. Student's t-test and one-way ANOVA were used to determine the statistical significance. P < 0.05 was considered as statistically significant difference.

Results
The effects of hypoxia and stemness on the survival of patients with LUAD
To understand the effect of hypoxia and stemness on lung cancer progression, 447 patients (in TCGA database) were divided into 5 groups by unsupervised two-dimensional hierarchical clustering according to the
hypoxia and stemness index: cluster 1 (N = 177), cluster 2 (N = 152), cluster 3 (N = 68), cluster 4 (N = 44) and cluster 5 (N = 6) (Fig. 1a). Then, we compared the differences in disease-free survival (DFS) among the different groups (Fig. 1b). The difference in DFS between cluster 3 and cluster 4 was significant (Fig. 1c), while the difference in DFS among other groups was not significant (Fig. 1b). Cluster analysis revealed that the stemness and hypoxia index of cluster 3 was lower, while the stemness and hypoxia index of cluster 4 was higher (Fig. 1a). In addition, we validated the combined hypoxia and tumor cell stemness status classifiers model using GSE31210. Patients were classified into 3 clusters: cluster a (N = 103), cluster b (N = 105) and cluster c (N = 13) (Fig. 1d). DFS of clusters was analyzed (Fig. 1e). Considering that the number of samples in cluster c was too small, we compared the prognosis of cluster a and b. The prognosis of cluster b was more satisfactory than cluster a (Fig. 1f). However, the stemness and hypoxia index of cluster a was higher than cluster b (Fig. 1d). These results were consistent with the analysis results of TCGA database, indicating that the combined hypoxia and tumor cell stemness status classifiers model was feasible. Hence, we mainly focus on cluster 3 and cluster 4 (in TCGA database) in the follow-up.

Furthermore, the expression of epithelial-mesenchymal transition (EMT) regulatory genes in different clusters were analyzed. The results suggested that the expression levels of SNAI1 and ZEB1 in cluster 4 were notably higher than those in cluster 3 (Fig. 2a, b). However, there was no significant difference in CDH1 expression between cluster 3 and cluster 4 (Fig. 2c).

**Regulation of stemness and hypoxia on mRNA expression**

We found the transcript levels of 4341 mRNAs to be enhanced, and 2526 mRNAs to be repressed in cluster 3 compared with cluster 4 (Fig. 3a), implying that hypoxia and stemness obviously affected mRNAs expression at the genome-wide level. CIQTNF7, ADH1B, GRIA1, GGTL1C1 and CD207 were the top 5 upregulated mRNAs (Fig. 3b). PBK, TPX2, NEIL3, MYBL2 and FAM64A were the top 5 downregulated mRNAs (Fig. 3b). Through GO analysis of 6867 DE mRNAs (including 4341 upregulated mRNAs and 2526 downregulated mRNAs), we found that the differential mRNAs were mainly involved in DNA replication, nuclear division and chromosome segregation (Fig. 3c). Congruently, KEGG analysis revealed that metabolic pathways of DE mRNAs enrichment were related to DNA replication and mitosis (Fig. 3d). The relationship of DE mRNAs was analyzed using the PPI network. Hub genes of PPI network were identified corresponded to MCC score and showed in Fig. 3e.

**Effects of hub genes expression on survival of patients with LUAD**

Kaplan–Meier curves were plotted to analyze the relationship between the expression of 20 hub genes and overall survival. In TCGA database, patients with high expression of CENFP, BUB1, BUB1B, KIF23 and TTK had poor prognosis, indicating that these gene expressions were beneficial to LUAD progression (Fig. 4). However, the expression of other hub genes had no significant effect on the prognosis of patients with LUAD. In Kaplan Meier-plotter database, the prognostic analysis results of the 20 hub genes were consistent with the results of the TCGA database (Fig. 5).

**Regulation of stemness and hypoxia on lncRNA and miRNA expression**

In order to further understand the effect of stemness and hypoxia on gene expression of LUAD cells, we screened the DE IncRNA between cluster 3 and cluster 4. There were a total of 807 DE IncRNAs, of which 564 IncRNAs were upregulated and 243 IncRNAs were downregulated (Fig. 6a). The DE IncRNAs were ranked according to FC. The top 5 upregulated IncRNAs and the top 5 downregulated IncRNAs were shown in Fig. 6b. Congruently, we estimated the HRs of the 807 DE IncRNAs. The DE IncRNAs which risk score could independently predict the overall survival of patients were displayed in Fig. 6c.

We also identified 77 upregulated miRNAs and 166 downregulated miRNAs in cluster 3 compared with cluster 4 (Fig. 7a). The top 5 upregulated miRNAs were...
has-miR-133a-3p, has-miR-1-3p, has-miR-34b-3p, has-miR-1247-5p and has-miR-514a-3p (Fig. 7b). The top 5 downregulated miRNAs were has-miR-4652-5p, has-miR-9-5p, has-miR-9-3p, has-miR-105-5p and has-miR-767-5p (Fig. 7b). In total, 14 DE miRNAs with significant influence on prognosis were obtained by Kaplan–Meier curve and log-rank test (Fig. 7c).
CeRNA network analysis

The ceRNA network was constructed by using the hub genes, DE lncRNA and DE miRNA, which significantly affected prognosis. LncRNA-miRNA-mRNA ceRNA network was based on the following principles: LncRNA directly interacts by invoking miRNA sponge to regulate mRNA activity, and the expression correlation among lncRNA, miRNA and mRNA. Finally, we obtained a ceRNA network, “AC079160.1-miR-539-5p-CENPF” (Fig. 8a). The correlation relationship among the expression levels of CENPF, AC079160.1, miR-539-5p, tumor hypoxia and stemness index was evaluated. The expression level of CENPF was positively correlated with AC079160.1 expression, hypoxia and stemness index, but negatively correlated with miR-539-5p expression (Fig. 8b). miR-539-5p expression level was negatively correlated with hypoxia and stemness index (Fig. 8b). AC079160.1 expression was positively correlated with hypoxia and stemness index (Fig. 8b). Subsequently, we analyzed the expression of miR-539-5p and EGFR in different clusters. As expected, the expression of miR-539-5p in cluster 4 was significantly lower than other clusters, while the expression of EGFR in cluster 4 was notably higher than other clusters (Fig. 8c, d).

Since CENPF is one of the key DE genes, we analyzed the copy number variation of CENPF using cBioPortal...
Fig. 5 Prognostic analysis of CENPF (a), BUB1 (b), BUB1B (c), KIF23 (d) and TTK (e) in Kaplan Meier-plotter database
database. CENPF was altered in 13% (including 6% amplification and 7% mutation) of LUAD patients/samples (Fig. 9a). However, further survival analysis showed that the copy number variation of CENPF does not affect the prognosis of patients (Fig. 9b).

Discussion
In recent years, significant progress has been made in the treatment of LUAD. The survival rate of patients with LUAD has improved, but the efficacy of its treatment is still not satisfactory. The 5-year overall survival rate of LUAD is only 15% [4]. Therefore, exploring new treatment strategies for LUAD have become the focus of current research. Intratumoral hypoxia and tumor cell stemness are associated with patient outcome in various solid tumor [5, 6, 10]. However, these factors have not yet considered for treatment selection in LUAD due to lack of validated biomarkers. This study obtained expression data of LUAD from TCGA database, and explored a combined hypoxia and tumor cell stemness status classifiers model. Our study showed that LUAD patients with high hypoxia and stemness index have a poor prognosis, while those with low hypoxia and stemness index have a better prognosis. The classifiers model explored in this study was validated using GSE31210, and the results were consistent with the analysis results of TCGA. This reflected the rationality and usability of the classification model. Hypoxia and stemness are important regulators of EMT. E-cadherin, encoded by CDH1, is a key factor in inhibiting EMT [28]. SNAI1 and ZEB1 are important transcription factors that promote the progress of EMT, and play a key role in the occurrence and development of a variety of cancers [29]. Our results indicated that although the difference of CDH1 expression in each cluster was not obvious, the expression of SNAI1 and ZEB1 in the high hypoxia and stemness index cluster (cluster 4) was significantly upregulated. Therefore, systematic analysis of
the relationship between tumor hypoxia and stemness can provide a more targeted research area and a new perspective to reveal the underlying mechanism of cancer.

Hypoxia affects stem cell phenotype through multiple signaling pathways [30–32]. In this study, we obtained 6867 protein-coding genes related to hypoxia and tumor stemness. Annotation and functional analysis showed that these genes were mainly involved in cell cycle and DNA replication. These results suggested that hypoxia-induced tumor stem cells have potent proliferation ability. Studies have shown that hypoxia can make lung cancer, glioma and prostate cancer cells to express stem cell characteristics, maintain their undifferentiated state, or increase the number of tumor stem cells [33, 34]. To further screen the key genes in the hypoxia associated tumor stemness during LUAD progression, we constructed a PPI network and performed prognostic analysis. CENPF, BUB1, BUB1B, KIF23 and TTK were identified as the key potential genes affecting hypoxia associated tumor stemness in this study. CENPF is a protein associated with the centromere-kinetochore complex [35]. Studies have demonstrated that breast cancer patients with high expression of CENPF in tumor tissue are more prone to bone metastasis [36]. The process of tumor bone metastasis is usually accompanied by the enhancement of hypoxia and stemness of tumor cells [37]. BUB1 and BUB1B are key components of the mitotic checkpoint complex. Abnormal expression or mutation of BUB1 or BUB1B can lead to aneuploidy. Considering that aneuploidy is common in many types of
In conclusion, we found that CENPF, BUB1, BUB1B, KIF23 and TTK were potential key genes involved in regulating hypoxia-induced tumor cell stemness. Additionally, we found that the "AC079160.1-miR-539-5p-CENPF" axis was an important regulatory pathway in hypoxia-induced tumor cell stemness.
Acknowledgements
The author sincerely appreciates the support of all members of the laboratory for this research.

Authors’ contributions
Junfang Tang conceived the original idea and oversaw the work’s findings. Lili Guo conducted data analysis and manuscript writing. Hongxia Li and Weiying Li were involved in the interpretation of data. All authors read and approved the final manuscript.

Funding
This study was supported by The Beijing CSCO-Hengrui Oncology Research Foundation (Y-HR2018-119).

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author (Email: tangjf1969@163.com) on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China. 2 Department of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.

Received: 10 July 2020   Accepted: 25 October 2020
Published online: 04 November 2020

Fig. 9  Prognostic analysis of the copy number variation of CENPF. a Alteration frequency of CENPF in LUAD. b Overall survival of patients in unaltered group (N = 200) and altered group (N = 30).

References
1. Li J, Zhang X, Tang J, Gong C. MicroRNA-374b-5p functions as a tumor suppressor in non-small cell lung cancer by targeting FOXP1 and predicts prognosis of cancer patients. Onco Targets Ther. 2020;13:4229–37.
2. Wang W, He J, Lu H, Kong Q, Lin SS. KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis. Biosci Rep. 2020;40(7):BSR20193468.
3. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:555–67.
4. Yu J, Hou M, Pei T. FAM83A is a prognosis signature and potential onco-gene of lung adenocarcinoma. DNA Cell Biol. 2020;39:890–9.
5. Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16:225–38.
6. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–34.
7. Abbassadegan MR, Bagheri V, Razavi MS, Montaza AA, Sahebkar A, et al. Isolation, identification, and characterization of cancer stem cells: a review. J Cell Physiol. 2017;232:2008–18.
8. Samonig L, Loipetzberger A, Blochl C, Runik M, Kohlbacher O, et al. Proteins and molecular pathways relevant for the malignant properties of tumor-initiating pancreatic cancer cells. Cells. 2020;9:1397.
9. Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomed. 2018;13:6049–58.
30. Semenza GL. Hypoxia-inducible factors: coupling glucose metabolism and epidermal growth factor receptor in breast cancer. Sci Rep. 2018;8:2073.

31. Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2007;6:781–90.

32. Schwarzer A, Emmrich S, Schmidt F, Beck D, Ng M, et al. The non-coding RNA landscape of human hematopoiesis and leukemia. Nat Commun. 2017;8:218.

33. Colwell N, Pahlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016;164:152–69.

34. Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111.

35. Fritzler MJ, Rattner JB, Luft LM, Edworth SM, Casiano CA, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev. 2011;10:194–200.

36. Sun J, Huang, J, Lan J, Zhou K, Gao Y, et al. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. Cancer Cell Int. 2019;19:264.

37. Zeng W, Wan R, Zheng Y, Singh SR, Wei Y. Hypoxia, stem cells and bone tumor. Cancer Lett. 2011;313:129–36.

38. Myrie KA, Percy MJ, Azim JN, Neeley CK,etty EM. Mutation and expression analysis of human BUB1 and BUB1B in aneuploid breast cancer cell lines. Cancer Lett. 2000;152:193–9.

39. Sun X, Jin Z, Song X, Wang J, Li Y, et al. Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma. BMC Cancer. 2015;15:961.

40. Wang S, Zhang M, Liang D, Sun W, Zhang C, et al. Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. Eur J Med Chem. 2019;175:247–68.

41. Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3:1113–21.

42. Deng H, Qianqian G, Ting J, Aimin Y. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. Biomed Pharmacother. 2018;106:1072–81.

43. Yu H, Gao G, Cai J, Song H, Ma Z, et al. MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. Exp Mol Pathol. 2019;108:143–9.

44. Guo J, Gong G, Zhang B. miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer. Sci Rep. 2018;8:2073.

45. Sun H, Sun Y. Lidocearn inhibits proliferation and metastasis of lung cancer cell via regulation of miR-539/EGFR axis. Art Cell Nanomed Biotechnol. 2019;4:2866–74.

46. Nijkamp MM, Span PN, Bussink J, Kaanders JH. Interaction of EGFR with EGFR ligands: a new paradigm. Cancer Res. 2017;77:3965–81.

47. Huang Y. The novel regulatory role of IncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med. 2018;22:5768–75.

48. Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81.

49. Jen J, Tang YA, Lu YH, Lin CC, Lai WW, et al. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol Cancer. 2017;16:104.

50. Loewen G, Jayawickramarajah J, Zhuo Y, Shan B. Functions of IncRNA HOTAIR in lung cancer. J Hematol Oncol. 2014;7:90.